Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 9/20 | 0.60 |
| ▸ | F13A1 | P00488 | 6/20 | 0.60 |
| ▸ | TGM1 | P22735 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410584 | 0.95 | TGM2 (0.65) | ALDH1A1POLBPKMHTTTGM2 | |
| SCHEMBL12550181 | 0.89 | LMNA (0.60) | POLBTGM2F13A1TGM1LMNA | |
| SCHEMBL1917656 | 0.89 | TGM2 (0.64) | POLBPKMTGM2F13A1TGM1 | |
| SCHEMBL14490210 | 0.89 | TGM2 (0.59) | ALDH1A1PKMTGM2F13A1TGM1 | |
| SCHEMBL1955143 | 0.88 | TGM2 (0.58) | ALDH1A1PKMTGM2F13A1TGM1 | |
| SCHEMBL24693750 | 0.86 | TGM2 (0.56) | POLBPKMTGM2F13A1TGM1 | |
| SCHEMBL6977995 | 0.86 | TGM2 (0.58) | ALDH1A1POLBTGM2F13A1TGM1 | |
| SCHEMBL14490221 | 0.84 | ABL1 (0.55) | ALDH1A1PKMHTTTGM2F13A1 | |
| SCHEMBL23788561 | 0.83 | ALDH1A1 (0.62) | ALDH1A1TGM2F13A1TGM1LMNA | |
| SCHEMBL5253160 | 0.83 | POLB (0.70) | POLBTGM2F13A1TGM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110129542-A1 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION | 2011-06-02 | — | — | US | claimed |
| EP-2190820-A2 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2010-06-02 | — | — | EP | claimed |
| WO-2009023664-A2 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2009-02-19 | — | — | WO | claimed |
| US-20110129542-A1 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129542-A1 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | HSD11B1, HSD17B1, HSD3B1 | ALDH1A1 45/4885POLB 2900/4885PKM 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.